skip navigation


Register for Latest Research

Stay Informed
Register with NCJRS to receive NCJRS's biweekly e-newsletter JUSTINFO and additional periodic emails from NCJRS and the NCJRS federal sponsors that highlight the latest research published or sponsored by the Office of Justice Programs.

NCJRS Abstract

The document referenced below is part of the NCJRS Virtual Library collection. To conduct further searches of the collection, visit the Virtual Library. See the Obtain Documents page for direction on how to access resources online, via mail, through interlibrary loans, or in a local library.


NCJ Number: 194395 Find in a Library
Title: Expanded Biodefense Role for the National Institutes of Health
Author(s): Anthony Fauci M.D.
Date Published: April 2000
Page Count: 5
Sponsoring Agency: National Institute of Allergy and Infectious Diseases (NIAID)
Bethesda, MD 20892
Sale Source: National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health
9000 Rockville Pike
Bethesda, MD 20892
United States of America
Document: HTML
Type: Issue Overview
Format: Document
Language: English
Country: United States of America
Annotation: This paper considers the increased funding and expanded role for the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), in preparing for an expanded "biodefense" role.
Abstract: The President's Budget for fiscal year 2003 contains $4 billion for the NIAID, a $1.5 billion increase over the 2002 allocation and the largest single increase for an Institute in the history of the NIH. The NIAID budget includes $1.7 billion for defending against bioterrorism. Dr. Anthony Fauci, the director of NIAID, states that to defend against bioterrorism, the Institute is focusing on major threats, classed as category "A" agents, i.e., smallpox, anthrax, tularemia, plague, botulism toxin, and hemorrhagic fever viruses; it is also looking at category "B" and "C" agents, such as foodborne E. coli and staphylococcus. The planned effort will be generic to virtually all microbes that might be used in bioterrorism. The NIAID will continue its cooperation with the Army Medical Research Institute of Infectious Diseases, but with new attention to cooperation with the biodefense command. Dr. Fauci states that the goal within the next 20 years is to have "bug to drug" within 24 hours. This would meet the challenge of genetically engineered bioagents. Someone might genetically engineer a microbe and make it resistant to the standard treatment, but if that trait is identified, another drug does not have to be created to counter it. Dr. Fauci discusses the issue of smallpox and some of the issues that must be addressed in the area of large-scale vaccination. Issues in the area of local and State public health systems are also discussed, along with research and information dissemination.
Main Term(s): Domestic Preparedness
Index Term(s): Biological weapons; Communicable diseases; Diseases; Healthcare; Terrorist tactics; Terrorist weapons; US Department of Health and Human Services
Note: Downloaded April 25, 2002.
To cite this abstract, use the following link:

*A link to the full-text document is provided whenever possible. For documents not available online, a link to the publisher's website is provided. Tell us how you use the NCJRS Library and Abstracts Database - send us your feedback.